SNOA News and Press, Sonoma Pharmaceuticals Inc. From 11/13/23

Gross profit percentage of 36% for the quarter, up 1% from first fiscal quarter 2024 Total operating expenses decreased for the quarter and six months ended September 30, 2023 compared to same period prior year European revenues increased 3% for the quarter and 13% for the six months ended ...

INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...

Sonoma Pharmaceuticals Inc. (SNOA) is expected to report for Q2 2024

2023-11-03 16:44:50 ET More on Sonoma Pharmaceuticals Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals Historical earnings data for Sonoma Pharmaceuticals Financial information for Sonoma Pharmaceuticals For further details see: Sonoma Pharma...

BOULDER, CO / ACCESSWIRE / November 3, 2023 / Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and n...

2023-10-26 09:28:45 ET More on Sonoma Pharmaceuticals Seeking Alpha’s Quant Rating on Sonoma Pharmaceuticals Historical earnings data for Sonoma Pharmaceuticals Financial information for Sonoma Pharmaceuticals For further details see: Sonoma Pharma...

BOULDER, CO / ACCESSWIRE / October 26, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, today announced the pricing of its...

JUPITER, Fla., Sept. 21, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- Dawson James Securities, Inc. (“Dawson”), a full-service investment bank focused on emerging growth companies, today announces its 8 th Annual Dawson James Small Cap Growth Conferen...

BOULDER, CO / ACCESSWIRE / August 15, 2023 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn ® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound, eye, oral and na...

2023-08-10 17:43:58 ET Sonoma Pharmaceuticals press release ( NASDAQ: SNOA ): FQ1 GAAP EPS of -$0.29. Revenue of $3.4M (-15.0% Y/Y). Shares -0.09% AH. For further details see: Sonoma Pharmaceuticals GAAP EPS of -$0.29, revenue of $3.4M